JP2011509298A5 - - Google Patents

Download PDF

Info

Publication number
JP2011509298A5
JP2011509298A5 JP2010542313A JP2010542313A JP2011509298A5 JP 2011509298 A5 JP2011509298 A5 JP 2011509298A5 JP 2010542313 A JP2010542313 A JP 2010542313A JP 2010542313 A JP2010542313 A JP 2010542313A JP 2011509298 A5 JP2011509298 A5 JP 2011509298A5
Authority
JP
Japan
Prior art keywords
alkyl
aryl
stereoisomer
halogen
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010542313A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011509298A (ja
JP5649454B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/030229 external-priority patent/WO2009089224A1/en
Publication of JP2011509298A publication Critical patent/JP2011509298A/ja
Publication of JP2011509298A5 publication Critical patent/JP2011509298A5/ja
Application granted granted Critical
Publication of JP5649454B2 publication Critical patent/JP5649454B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010542313A 2008-01-08 2009-01-06 ミトコンドリア病の処置のための（ヘテロ）アリール−ｐ−キノン誘導体 Expired - Fee Related JP5649454B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1038708P 2008-01-08 2008-01-08
US1040908P 2008-01-08 2008-01-08
US61/010,409 2008-01-08
US61/010,387 2008-01-08
PCT/US2009/030229 WO2009089224A1 (en) 2008-01-08 2009-01-06 (HET) ARYL-p-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013268441A Division JP2014058569A (ja) 2008-01-08 2013-12-26 ミトコンドリア病の処置のための（ヘテロ）アリール−ｐ−キノン誘導体

Publications (3)

Publication Number Publication Date
JP2011509298A JP2011509298A (ja) 2011-03-24
JP2011509298A5 true JP2011509298A5 (https=) 2013-02-28
JP5649454B2 JP5649454B2 (ja) 2015-01-07

Family

ID=40853439

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010542313A Expired - Fee Related JP5649454B2 (ja) 2008-01-08 2009-01-06 ミトコンドリア病の処置のための（ヘテロ）アリール−ｐ−キノン誘導体
JP2013268441A Withdrawn JP2014058569A (ja) 2008-01-08 2013-12-26 ミトコンドリア病の処置のための（ヘテロ）アリール−ｐ−キノン誘導体
JP2015236261A Withdrawn JP2016034979A (ja) 2008-01-08 2015-12-03 ミトコンドリア病の処置のための（ヘテロ）アリール−ｐ−キノン誘導体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013268441A Withdrawn JP2014058569A (ja) 2008-01-08 2013-12-26 ミトコンドリア病の処置のための（ヘテロ）アリール−ｐ−キノン誘導体
JP2015236261A Withdrawn JP2016034979A (ja) 2008-01-08 2015-12-03 ミトコンドリア病の処置のための（ヘテロ）アリール−ｐ−キノン誘導体

Country Status (6)

Country Link
US (2) US8952071B2 (https=)
EP (1) EP2237664A4 (https=)
JP (3) JP5649454B2 (https=)
CA (1) CA2708961C (https=)
EA (1) EA023618B1 (https=)
WO (1) WO2009089224A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033092A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
EP2471530B1 (en) * 2005-06-01 2017-01-11 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US9278085B2 (en) 2006-02-22 2016-03-08 Edison Pharmaceuticals, Inc. Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
WO2009061744A2 (en) 2007-11-06 2009-05-14 Edison Pharmaceuticals, Inc. 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
EA023618B1 (ru) 2008-01-08 2016-06-30 Эдисон Фармасьютикалз, Инк. Производные (гет)арил-п-хинона для лечения митохондриальных болезней
WO2009111576A2 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
EP2262519A4 (en) * 2008-03-05 2011-03-23 Edison Pharmaceuticals Inc TREATMENT OF HEARING AND BALANCING DISORDERS WITH REDOXACTIVE THERAPEUTICS
WO2009158348A1 (en) * 2008-06-25 2009-12-30 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
EP2344142B1 (en) 2008-09-10 2024-06-26 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
EP2362726B1 (en) 2008-10-14 2018-08-08 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
CA2741767C (en) 2008-10-28 2017-09-12 Ptc Therapeutics, Inc. Process for the production of alpha-tocotrienol and derivatives
PL2424495T3 (pl) 2009-04-28 2018-06-29 Bioelectron Technology Corporation Leczenie dziedzicznej neuropatii nerwów wzrokowych lebera i dominującego zaniku nerwu wzrokowego chinonami tokotrienolu
DK2470168T3 (en) * 2009-08-26 2018-05-07 Bioelectron Tech Corp PROCEDURES FOR PREVENTION AND TREATMENT OF CEREBRAL ISCAM
EP3689342A1 (en) 2011-04-26 2020-08-05 Retrotope, Inc. Oxidative retinal diseases
AU2012249917B2 (en) 2011-04-26 2017-06-15 Biojiva Llc Neurodegenerative disorders and muscle diseases implicating PUFAs
AU2012249918B2 (en) 2011-04-26 2017-06-15 Biojiva Llc Impaired energy processing disorders and mitochondrial deficiency
AU2012249920B2 (en) 2011-04-26 2017-06-15 Biojiva Llc Disorders implicating PUFA oxidation
WO2012174286A1 (en) 2011-06-14 2012-12-20 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
JP2014520894A (ja) 2011-07-19 2014-08-25 エジソン ファーマシューティカルズ， インコーポレイテッド 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法
CA2883879A1 (en) 2012-09-07 2014-03-13 Edison Pharmaceuticals, Inc. Quinone derivatives for use in the modulation of redox status of individuals
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US10189830B2 (en) 2013-03-15 2019-01-29 Bioelectron Technology Corporation Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
CN106170206A (zh) 2014-03-13 2016-11-30 乐巢拓普有限公司 视神经病变治疗和用稳定的多不饱和物质减少类固醇诱导的氧化应激
AU2015364640B2 (en) 2014-12-16 2020-08-13 Ptc Therapeutics, Inc. Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
EP3390377B1 (en) 2015-12-16 2026-03-25 PTC Therapeutics, Inc. Improved methods for enriching alpha-tocotrienol from mixed tocol compositions
WO2017106803A1 (en) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
WO2018094116A1 (en) 2016-11-17 2018-05-24 Retrotope, Inc. Isotopically modified components and therapeutic uses thereof
KR20210076956A (ko) 2018-10-17 2021-06-24 피티씨 테라퓨틱스, 인크. α-시누클레인병증, 타우병증 및 기타 장애를 억제 및 치료하기 위한 2,3,5-트리메틸-6-노닐사이클로헥사-2,5-디엔-1,4-디온
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
PE20240893A1 (es) 2021-07-08 2024-04-24 Ptc Therapeutics Inc Composiciones farmaceuticas que comprenden 2,3,5-trimetil-6-nonilciclohexa-2,5-dien-1,4-diona

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57183782A (en) 1981-04-30 1982-11-12 Sumitomo Chem Co Ltd Preparation of coumarone compound
US6232060B1 (en) * 1996-01-19 2001-05-15 Galileo Laboratories, Inc. Assay system for anti-stress agents
US5801159A (en) * 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
US6426362B1 (en) * 1999-10-08 2002-07-30 Galileo Laboratories, Inc. Formulations of tocopherols and methods of making and using them
US6528042B1 (en) * 1999-10-08 2003-03-04 Galileo Laboratories, Inc. Compositions of flavonoids for use as cytoprotectants and methods of making and using them
WO2002047680A2 (en) * 2000-12-15 2002-06-20 Galileo Laboratories, Inc. Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia
US7034054B2 (en) * 2000-12-15 2006-04-25 Galileo Pharmaceuticals, Inc. Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols
US6608196B2 (en) * 2001-05-03 2003-08-19 Galileo Pharmaceuticals, Inc. Process for solid supported synthesis of pyruvate-derived compounds
NZ513547A (en) * 2001-08-13 2002-09-27 Antipodean Biotechnology Ltd Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone)
WO2003015494A2 (en) * 2001-08-21 2003-02-27 Galileo Pharmaceuticals, Inc. Tocopherol enriched compositions and amelioration of inflammatory symptoms
AU2002352726A1 (en) * 2001-11-15 2003-06-10 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
US6667330B2 (en) 2002-01-31 2003-12-23 Galileo Pharmaceuticals, Inc. Furanone derivatives
US6653346B1 (en) * 2002-02-07 2003-11-25 Galileo Pharmaceuticals, Inc. Cytoprotective benzofuran derivatives
US7078541B2 (en) * 2002-02-07 2006-07-18 Galileo Pharmaceuticals, Inc. Benzofuran derivatives
GB0204232D0 (en) * 2002-02-22 2002-04-10 Isis Innovation Assay
DE60211875T2 (de) 2002-07-01 2006-10-26 Santhera Pharmaceuticals (Schweiz) Ag Screeningverfahren und Verbindungen zur Behandlung von Friedreich ataxia
JP4599292B2 (ja) * 2002-10-30 2010-12-15 エジソン ファーマシューティカルズ， インコーポレイテッド 物理的−化学的特性に基づく治療用化合物の同定
WO2005033092A1 (en) * 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
US7393662B2 (en) * 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
EP2471530B1 (en) * 2005-06-01 2017-01-11 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
CA2622523C (en) * 2005-09-15 2014-02-18 Edison Pharmaceuticals, Inc. Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US9278085B2 (en) * 2006-02-22 2016-03-08 Edison Pharmaceuticals, Inc. Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US7939554B2 (en) 2006-06-28 2011-05-10 The Cleveland Clinic Foundation Protein phosphatase inhibitors
WO2008086025A2 (en) * 2007-01-10 2008-07-17 Edison Pharmaceuticals, Inc. Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity
WO2009061744A2 (en) * 2007-11-06 2009-05-14 Edison Pharmaceuticals, Inc. 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
WO2009088572A2 (en) * 2008-01-07 2009-07-16 Centocor, Inc. Method of treating erythropoietin hyporesponsive anemias
EA023618B1 (ru) 2008-01-08 2016-06-30 Эдисон Фармасьютикалз, Инк. Производные (гет)арил-п-хинона для лечения митохондриальных болезней
EP2262519A4 (en) * 2008-03-05 2011-03-23 Edison Pharmaceuticals Inc TREATMENT OF HEARING AND BALANCING DISORDERS WITH REDOXACTIVE THERAPEUTICS
WO2009111576A2 (en) * 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
CA2723621A1 (en) * 2008-05-15 2009-11-19 Edison Pharmaceuticals, Inc Treatment of hearing and balance impairments using compounds having erythropoietin activity
WO2009143268A2 (en) * 2008-05-22 2009-11-26 Edison Pharmaceuticals, Inc. Treatment of mitochondrial diseases with an erythropoietin mimetic
WO2009158348A1 (en) * 2008-06-25 2009-12-30 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
WO2010005989A1 (en) * 2008-07-09 2010-01-14 Edison Pharmaceuticals, Inc. Dermatological compositions with anti-aging and skin even-toning properties
US20100029784A1 (en) * 2008-07-30 2010-02-04 Hinman Andrew W Naphthoquinone compositions with anti-aging, anti-inflammatory and skin even-toning properties
EP2344142B1 (en) * 2008-09-10 2024-06-26 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
EP2362726B1 (en) * 2008-10-14 2018-08-08 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
CA2741767C (en) * 2008-10-28 2017-09-12 Ptc Therapeutics, Inc. Process for the production of alpha-tocotrienol and derivatives
EP2424360A4 (en) * 2009-04-28 2012-10-03 Ampere Life Sciences Inc TOPICAL, PERIOCULAR OR INTRAOCULAR USE OF TOCOTRIENOLS FOR THE TREATMENT OF OPHTHALMIC DISEASES
PL2424495T3 (pl) * 2009-04-28 2018-06-29 Bioelectron Technology Corporation Leczenie dziedzicznej neuropatii nerwów wzrokowych lebera i dominującego zaniku nerwu wzrokowego chinonami tokotrienolu
JP2012525397A (ja) * 2009-04-28 2012-10-22 エジソン ファーマシューティカルズ， インコーポレイテッド 眼科疾患を治療するためのトコトリエノールキノンの製剤
EP2609921A1 (en) * 2009-06-25 2013-07-03 Ampere Life Sciences, Inc. Treatment of pervasive developmental disorders with tocotrienols or tocotrienol enriched extracts
DK2470168T3 (en) * 2009-08-26 2018-05-07 Bioelectron Tech Corp PROCEDURES FOR PREVENTION AND TREATMENT OF CEREBRAL ISCAM
WO2011041452A2 (en) 2009-10-01 2011-04-07 Ampere Life Sciences, Inc. Mouse model for identifying compounds for the treatment of oxidative stress
US20110172312A1 (en) * 2009-12-31 2011-07-14 Miller Guy M Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
WO2011113018A1 (en) 2010-03-12 2011-09-15 Ampere Life Sciences, Inc. Measurement and control of biological time
AU2011238525A1 (en) * 2010-04-06 2012-11-08 Edison Pharmaceuticals, Inc. Treatment of Ataxia Telangiectasia
CA2797581A1 (en) * 2010-04-27 2011-11-03 Edison Pharmaceuticals, Inc. Formulations of quinones for the treatment of ophthalmic diseases
US20120101169A1 (en) * 2010-07-14 2012-04-26 Penwest Pharmaceuticals Co. Methods of providing anticoagulation effects in subjects
EA201300215A1 (ru) 2010-08-06 2013-07-30 Эдисон Фармасьютикалз, Инк. Лечение митохондриальных болезней нафтохинонами
EP2601168A4 (en) 2010-08-06 2013-12-04 Ampere Life Sciences Inc TREATMENT OF MITOCHONDRIAL DISEASES BY VITAMIN K
WO2012068552A1 (en) * 2010-11-19 2012-05-24 Edison Pharmaceuticals, Inc. Methods for improving blood glucose control
WO2012154613A1 (en) 2011-05-06 2012-11-15 Edison Pharmaceuticals, Inc. Improved process for the preparation of d-alpha-tocotrienol from natural extracts
WO2012170773A1 (en) 2011-06-08 2012-12-13 Edison Pharmaceuticals, Inc. Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones
WO2012174286A1 (en) 2011-06-14 2012-12-20 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
WO2013006736A1 (en) 2011-07-06 2013-01-10 Edison Pharmaceuticals, Inc Treatment of leigh syndrome and leigh-like syndrome, including complications of sucla2 mutations, with tocotrienol quinones
US20150057363A1 (en) 2011-07-06 2015-02-26 Guy M. Miller Treatment of methylmalonic aciduria, isovaleric aciduria, and other organic acidurias with tocotrienol quinones
JP2014520894A (ja) 2011-07-19 2014-08-25 エジソン ファーマシューティカルズ， インコーポレイテッド 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法
CA2883879A1 (en) 2012-09-07 2014-03-13 Edison Pharmaceuticals, Inc. Quinone derivatives for use in the modulation of redox status of individuals
US10189830B2 (en) 2013-03-15 2019-01-29 Bioelectron Technology Corporation Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US20140275045A1 (en) 2013-03-15 2014-09-18 Edison Pharmaceuticals, Inc. Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
AU2014273891A1 (en) 2013-05-31 2015-12-24 Bioelectron Technology Corporation Carboxylic acid derivatives for treatment of oxidative stress disorders

Similar Documents

Publication Publication Date Title
JP2011509298A5 (https=)
JP2011525926A5 (https=)
JP2016520621A5 (https=)
BR112012011306A8 (pt) Composição para tratamento de superfície, seu processo de produção, e artigo tratado na superfície
EA201290128A1 (ru) Новые макроциклические ингибиторы репликации вируса гепатита с
US7999001B2 (en) Antiviral compounds and methods of using thereof
MX342806B (es) Compuestos y método para reducir el ácido úrico.
ECSP088208A (es) Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c
BRPI0910541B8 (pt) compostos de tetrazol
EA201100441A1 (ru) Соединения для коррекции уровня мочевой кислоты и способы их применения
AR047972A1 (es) Derivado de bencimidazol, proceso de obtencion y composiciones farmaceuticas.
NZ610012A (en) Compositions and methods of treating pulmonary hypertension
UA106209C2 (en) Choline cocrystal of 5-[(1z,2e)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidine acetic acid
CO6220957A2 (es) 4-2-(4-metilfenilsulfanil-fenil piperidina con inhibicion combinada de recaptacion de serotonina y norepinefrina para el tratamiento del trastorno de deficit de atencion e hiperactividad melancolia depresion resistente al tratamiento o sintomas resid
RU2013139163A (ru) Композиции с высокой проникающей способностью и способы лечения индуцированных патогенами нарушений тканей
MX2024014499A (es) Composiciones para tratar xlmtm
EA201001748A1 (ru) Соединения, используемые для лечения гепатита с
ATE522531T1 (de) Indolylpyrrolidine zur behandlung von krebs
BR112012033675A2 (pt) derivado de benzofurano para o tratamento de hepatite c
AR049773A1 (es) Derivados de tiadiazolurea. metodos de obtencion y composiciones farmaceuticas
BR112015006218A2 (pt) derivados de ariletinil
FR2958644B1 (fr) Composition cosmetique
WO2008085074A3 (en) 1, 3-dihydroimidazoles for treating cardiovascular disorders
SONG et al. Effects of FOXO3a on regulating mitophagy in hepatic ischemia reperfusion injury
BR112015002113A2 (pt) medicamento contra a doença do refluxo gastroesofágico